MARKET

HRMY

HRMY

Harmony Biosciences Holdings, Inc.
NASDAQ
34.24
-1.04
-2.95%
Closed 18:09 03/24 EDT
OPEN
35.86
PREV CLOSE
35.28
HIGH
35.99
LOW
33.83
VOLUME
593.09K
TURNOVER
0
52 WEEK HIGH
41.61
52 WEEK LOW
28.14
MARKET CAP
1.96B
P/E (TTM)
13.62
1D
5D
1M
3M
1Y
5Y
1D
Harmony Biosciences appoints Adam Zaeske as Chief Commercial Officer
Seeking Alpha · 21h ago
Harmony Biosciences: A Compelling Risk-Reward Opportunity
Seeking Alpha · 1d ago
Harmony Biosciences Appoints New Chief Commercial Officer
TipRanks · 1d ago
Harmony Biosciences CCO Jeffrey Dierks steps down, Adam Zaeske succeedsTakeda
TipRanks · 1d ago
HARMONY BIOSCIENCES NAMES ADAM ZAESKE AS CHIEF COMMERCIAL OFFICER TO LEAD THE NEXT PHASE OF COMMERCIAL GROWTH AS ITS PORTFOLIO EXPANDS
Reuters · 1d ago
Weekly Report: what happened at HRMY last week (0317-0321)?
Weekly Report · 1d ago
HRMY Investors Have Opportunity to Join Harmony Biosciences Holdings, Inc. Fraud Investigation with the Schall Law Firm
Barchart · 3d ago
HRMY Down 10.8% in Six Months: How Should You Play the Stock?
Barchart · 6d ago
More
About HRMY
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company. It is focused on developing and commercializing therapies for patients living with rare neurological diseases as well as patients living with other neurological diseases who have unmet medical needs. Its product, WAKIX (pitolisant), is a first-in-class molecule with a novel mechanism of action designed to enhance histamine signaling in the brain by binding to H3 receptors. Its WAKIX is developed for the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy and treatment of cataplexy in adult patients with narcolepsy. It also provides HBS-102, an investigational compound, which is a melanin-concentrating hormone receptor 1 (MCHR1) antagonist that targets MCH neurons in the brain. It also develops ZYN002, a pharmaceutically manufactured synthetic cannabidiol. It is also focused on the rare epilepsy franchise in its expanding late-stage pipeline of CNS assets: EPX-100 and EPX-200.

Webull offers Harmony Biosciences Holdings Inc stock information, including NASDAQ: HRMY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HRMY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading HRMY stock methods without spending real money on the virtual paper trading platform.